Budd-Chiari syndrome surgery

Budd-Chiari syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Budd-Chiari syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Budd-Chiari syndrome surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Budd-Chiari syndrome surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Budd-Chiari syndrome surgery
CDC on Budd-Chiari syndrome surgery
Budd-Chiari syndrome surgery in the news
Blogs on Budd-Chiari syndrome surgery
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Budd-Chiari syndrome surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Therapeutic paracentesis can be used for symptomatic treatment of ascites. Paracentesis can be associated with complications such as bacterial peritonitis. The benefits of therapeutic paracentesis must be carefully weighed against its risks.The choice of interventional procedures in the treatment of BCS is based on the type of venous occlusion.Aspiration thrombectomy followed by predilatation with a small diameter catheter. This is associated with a decreased risk of pulmonary embolism and allows the introduction of a thrombolytic catheter for administration of a thrombolytic agent.Endovascular treatment is indicated in patients with thrombosed IVC. Recanalization of the occluded IVC results in rapid clinical improvement.Angioplasty is recommended for patients with occluded hepatic vein and patent inferior vena cava.Stenting is preferred if the hepatic vein has a straight course and is of sufficient diameter (≥7 mm).Transjugular portosystemic shunt (TIPS) is recommended in patients who have developed liver cirrhosis. transjugular portosystemic shunt (TIPS) decreases porto-systemic gradient hence reducing the risk of variceal bleeding.Liver transplantation is the last rescue treatment when conservative and interventional therapy does not prevent the development of liver cirrhosis and progressive liver failure in chronic BCS.It is generally reserved for patients with fulminant hepatic failure, failure of shunts, or progression of cirrhosis that reduces the life expectancy to 1 year.

Surgery

Paracentesis

Therapeutic paracentesis can be used for symptomatic treatment of ascites. Paracentesis can be associated with complications such as bacterial peritonitis. The benefits of therapeutic paracentesis must be carefully weighed against its risks.

Interventional therapy

• The choice of interventional procedures in the treatment of BCS is based on the type of venous occlusion.
• Aspiration thrombectomy followed by predilatation with a small diameter catheter. This is associated with a decreased risk of pulmonary embolism and allows the introduction of a thrombolytic catheter for administration of a thrombolytic agent.
• Endovascular treatment is indicated in patients with thrombosed IVC. Recanalization of the occluded IVC results in rapid clinical improvement.
• Angioplasty is recommended for patients with occluded hepatic vein and patent inferior vena cava.
• Stenting is preferred if the hepatic vein has a straight course and is of sufficient diameter (≥7 mm).
• The hepatic vein is usually accessed through the internal jugular vein. Other options include percutaneous transhepatic approach or access through the femoral vein. In acute thrombosis, thrombolytic therapy alone has good results.
• Interventional treatment with stenting has a long-term patency of 97% in IVC and 91% in HV, but angioplasty alone has a high rate of restenosis.
• Anticoagulant therapy that has to be maintained for at least 6 months after the intervention. Restenosis occurs after stenting, is usually due to inadequate anticoagulant therapy.
• Transjugular portosystemic shunt (TIPS) is recommended in patients who have developed liver cirrhosis. transjugular

portosystemic shunt (TIPS) decreases porto-systemic gradient hence reducing the risk of variceal bleeding.

• The use of a TIPS stent covered with polytetrafluoroethylene (ePTFE) or TIPS stent-graft improves longterm patency rates compared to bare stents.

Liver Transplantation

• Liver transplantation is the last rescue treatment when conservative and interventional therapy does not prevent the development of liver cirrhosis and progressive liver failure in chronic BCS.
• It is generally reserved for patients with fulminant hepatic failure, failure of shunts, or progression of cirrhosis that reduces the life expectancy to 1 year.
• Requires careful evaluation of indication for liver transplantation. patients presenting with fulminant hepatic failure, it is an urgent indication.
• Patients after liver transplantation require life-long immunosuppressive therapy and long-term anticoagulation therapy.
• The most common complications of transplant include rejection, arterial or venous thromboses, and bleeding due to anticoagulation. Up to 10% of patients may have a recurrence of Budd-Chiari syndrome after the transplant.